IRVINE, Calif., July 6, 2007 (PRIME NEWSWIRE) -- "In a market populated by bright ideas and bold optimism it's often difficult for a company's genuine successes to stand out amid a chorus of hyperbole," stated SmallCap Sentinel analyst D.R. Clark. "In fact, it can be most difficult for companies endeavoring in the trenches to have their watershed moments be fully appreciated."
"So, when a leading publication identifies both the increasing interest in an industry and a company's rising stature therein, it should signal to investors that this company greatly exceeds the run-of-the-mill upstart," Clark added. "Such was the case for CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) which was prominently discussed in an intriguing article in Business Week regarding their core technology's applications in angiogenesis, the science of enabling the human body to grow new blood vessels."
"The Business Week article should foster interest in this heavily funded, heavily followed research arena and by extension for the companies featured in the story," Clark noted. "It's a must-read for anyone interested in biotechnology and the incredible potential of angiogenesis. It's also interesting to note that the author says that CVBT may be 'well ahead of the pack in developing an effective and economic angiogenic therapy-and setting new standards for cardiac care.'"
The Business Week article is presently available online at the link below and features information regarding angiogenesis-related equities Genzyme Corp. (Nasdaq:GENZ), Baxter International (NYSE:BAX), Boston Scientific (NYSE:BOS) and CardioVascular BioTherapeutics.
CVBT is a biopharmaceutical company developing formulations of its active pharmaceutical ingredient (API), Fibroblast Growth Factor-1, to treat a number of diseases characterized by inadequate blood flow to a tissue or organ. In addition to its cardiac clinical trial of FGF-1 (CVBT-141A) in Limited-Option Heart Patients, the Company is conducting FDA-authorized clinical trials of FGF-1 (CVBT-141B) for dermal wound healing in diabetics, and peripheral artery disease (CVBT-141C).
An informational report featuring Cardiovascular BioTherapeutics is available at: http://stockupticks.com/profiles/2-2-06.html.
To be featured in SmallCap Sentinel contact us at the number below.
Statements herein contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCap Sentinel/StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP isn't an investment advisor and this report isn't investment advice. MP has been paid $19,200 by CVBT. for preparation and distribution of this report and other advertising. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding subject companies.
The SmallCap Sentinel logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3664